Paul Anthony Mieyal

Directeur/Membre du Conseil chez Danube Pharmaceuticals, Inc.

Profil

Paul Anthony Mieyal currently works at Danube Pharmaceuticals, Inc., as Director, Microbiogen Pty Ltd., as Director, and Specialty Renal Products, Inc., as Director.
Dr. Mieyal also formerly worked at Wexford Capital LP, as Managing Director of Life Sciences Investments from 2006 to 2020, Nephros, Inc., as Director from 2015 to 2020, GlobeImmune, Inc., as Director from 2007 to 2012, Kirax Corp., as Director, Epiphany Biosciences, Inc., as Director, Reverse Medical Corp., as Director, Nile Therapeutics, Inc., as Director from 2007 to 2013, Capricor Therapeutics, Inc., as Independent Director in 2013, OncoVista Innovative Therapies, Inc., as Director from 2009 to 2010, Ellipse Technologies, Inc., as Director, OptiScan Biomedical Corp., as Director, Sophono, Inc., as Director, and Wechsler & Co., Inc., as Vice President in 2006.
Dr. Mieyal received his undergraduate degree from Case Western Reserve University and doctorate degree from New York Medical College.

Postes actifs de Paul Anthony Mieyal

Sociétés	Poste	Début
Danube Pharmaceuticals, Inc.	Directeur/Membre du Conseil	-
Microbiogen Pty Ltd.	Directeur/Membre du Conseil	-
Specialty Renal Products, Inc.	Directeur/Membre du Conseil	-

Anciens postes connus de Paul Anthony Mieyal

Sociétés	Poste	Fin
Wexford Capital LP	Gestionnaire de Portefeuille-Actions	01/12/2020
NEPHROS, INC.	Directeur Général	15/04/2015
CAPRICOR THERAPEUTICS, INC.	Directeur/Membre du Conseil	20/11/2013
Nile Therapeutics, Inc. /Old/	Directeur/Membre du Conseil	01/11/2013
ONCOVISTA INNOVATIVE THERAPIES, INC.	Directeur/Membre du Conseil	08/11/2010